{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T21:13:23Z","timestamp":1774991603765,"version":"3.50.1"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Zhejiang Provincial Medical and Health Technology Project","award":["2022RC226"],"award-info":[{"award-number":["2022RC226"]}]},{"name":"General project of Hangzhou Science and Technology Bureau","award":["202204B16"],"award-info":[{"award-number":["202204B16"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Endocr Disord"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Polycystic ovary syndrome (PCOS) is a common endocrine disorder that affects 5\u201318% of women worldwide. This disorder is characterized by two core pathological features: ovulatory dysfunction and hyperandrogenism.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Method<\/jats:title>\n            <jats:p>A retrospective analysis was conducted on cases treated at Hangzhou Women\u2019s Hospital from July 2021 to November 2023. Based on age, we conducted propensity score matching analysis in a 1:1 ratio and statistical analysis using SPSS software, plotted receiver operating characteristic curves, and obtained the area under the curve, the optimal anti-M\u00fcllerian hormone screening threshold, corresponding sensitivity, specificity, Youden index, correct diagnostic rate, positive predictive value, negative predictive value. Age-related anti-M\u00fcllerian hormone screening criteria with polycystic ovary syndrome were established and evaluated based on the optimal anti-M\u00fcllerian hormone screening cutoff for each group. The above results were validated by the validation group. And Kappa consistency test was conducted between the age-related anti-M\u00fcllerian hormone screening test and 2003 Rotterdam criteria for polycystic ovary syndrome.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>The screening criteria for age-related anti-M\u00fcllerian hormone with polycystic ovary syndrome were: \u22657.46 ng\/ml (20-24-year-old), \u2265\u20094.55 ng\/ml (25-29-year-old), \u2265\u20094.19 ng\/ml (30-34-year-old), \u2265\u20093.57 ng\/ml (35-39-year-old).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>Our research indicates that age specific AMH threshold values show promising sensitivity and specificity for PCOS screening in the validation cohort. These findings indicate the potential utility of AMH based screening, but emphasize the need for optimization and validation in larger multicenter studies before clinical implementation.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Clinical trial number<\/jats:title>\n            <jats:p>Not applicable.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s12902-025-01975-4","type":"journal-article","created":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T09:40:09Z","timestamp":1751362809000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Establishment of age-related AMH screening cutoffs in Chinese women with PCOS: a retrospective study using propensity score matching analysis"],"prefix":"10.1186","volume":"25","author":[{"given":"Zhen","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaojing","family":"Teng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanfei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yonghai","family":"Shen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lin","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,7,1]]},"reference":[{"issue":"9","key":"1975_CR1","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1016\/S2213-8587(22)00163-2","volume":"10","author":"AE Joham","year":"2022","unstructured":"Joham AE, Norman RJ, Stener-Victorin E, Legro RS, Franks S, Moran LJ, et al. Polycystic ovary syndrome. Lancet Diabetes Endocrinol. 2022;10(9):668\u201380.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"9","key":"1975_CR2","doi-asserted-by":"publisher","first-page":"2562","DOI":"10.1093\/humrep\/det262","volume":"28","author":"R Li","year":"2013","unstructured":"Li R, Zhang Q, Yang D, Li S, Lu S, Wu X, et al. Prevalence of polycystic ovary syndrome in women in china: a large community-based study. Hum Reprod. 2013;28(9):2562\u20139.","journal-title":"Hum Reprod"},{"issue":"4","key":"1975_CR3","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1159\/000358485","volume":"77","author":"J Zhuang","year":"2014","unstructured":"Zhuang J, Liu Y, Xu L, Liu X, Zhou L, Tang L, et al. Prevalence of the polycystic ovary syndrome in female residents of chengdu, China. Gynecol Obstet Invest. 2014;77(4):217\u201323.","journal-title":"Gynecol Obstet Invest"},{"key":"1975_CR4","unstructured":"Xianqin M, Jinyu L, Liping Z, editors. etc. Investigation on the prevalence of polycystic ovary syndrome and analysis of related risk factors in Daxing District, Beijing. China Maternal and Child Health Care. 2021;36 (24):5764-7."},{"issue":"1","key":"1975_CR5","doi-asserted-by":"publisher","first-page":"74","DOI":"10.21037\/apm-20-1893","volume":"10","author":"Q Wu","year":"2021","unstructured":"Wu Q, Gao J, Bai D, Yang Z, Liao Q. The prevalence of polycystic ovarian syndrome in Chinese women: a meta-analysis. Annals Palliat Med. 2021;10(1):74\u201387.","journal-title":"Annals Palliat Med"},{"key":"1975_CR6","unstructured":"Cao Z. Zhonghua Fuchanke [Chinese Obstetrics and Gynecology]. 3rd ed. People\u2019s Medical Publishing House; 2014."},{"key":"1975_CR7","doi-asserted-by":"crossref","unstructured":"Pepinsky R, Sinclair L, Chow E et al. Proteolytic processing of mullerian inhibiting substance produces a transforming growth factor-beta-like fragment. 1988;263(35):18961-4.","DOI":"10.1016\/S0021-9258(18)37375-7"},{"issue":"8","key":"1975_CR8","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1093\/molehr\/gat024","volume":"19","author":"JV Jeppesen","year":"2013","unstructured":"Jeppesen JV, Anderson RA, Kelsey TW, Christiansen SL, Kristensen SG, Jayaprakasan K, et al. Which follicles make the most anti-Mullerian hormone in humans? Evidence for an abrupt decline in AMH production at the time of follicle selection. Mol Hum Reprod. 2013;19(8):519\u201327.","journal-title":"Mol Hum Reprod"},{"issue":"2","key":"1975_CR9","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1093\/molehr\/gah015","volume":"10","author":"C Weenen","year":"2004","unstructured":"Weenen C. Anti-Mullerian hormone expression pattern in the human ovary: potential implications for initial and Cyclic follicle recruitment. Mol Hum Reprod. 2004;10(2):77\u201383.","journal-title":"Mol Hum Reprod"},{"issue":"5","key":"1975_CR10","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1093\/humrep\/deq019","volume":"25","author":"CY Andersen","year":"2010","unstructured":"Andersen CY, Schmidt KT, Kristensen SG, Rosendahl M, Byskov AG, Ernst E. Concentrations of AMH and inhibin-B in relation to follicular diameter in normal human small antral follicles. Hum Reprod. 2010;25(5):1282\u20137.","journal-title":"Hum Reprod"},{"issue":"3","key":"1975_CR11","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1210\/jc.2005-2076","volume":"91","author":"P Pigny","year":"2006","unstructured":"Pigny P, Jonard S, Robert Y, Dewailly D. Serum Anti-M\u00fcllerian hormone as a surrogate for antral follicle count for definition of the polycystic ovary syndrome. J Clin Endocrinol Metabolism. 2006;91(3):941\u20135.","journal-title":"J Clin Endocrinol Metabolism"},{"key":"1975_CR12","unstructured":"Li R, Xu H, Jin L et al. Expert Consensus on Clinical Application of Anti-M\u00fcllerian Hormone (2023 Edition). Chinese Journal of Practical Gynecology and Obstetrics. 2023;39(04):431-9."},{"key":"1975_CR13","unstructured":"Diagnostics R. Instructions of anti Mullerian hormone detection kit (Electrochemiluminescence Method). 2023."},{"key":"1975_CR14","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.cca.2019.11.003","volume":"502","author":"X Zeng","year":"2020","unstructured":"Zeng X, Xie Y-j, Liu Y-t, Long S-l. Mo Z-c. Polycystic ovarian syndrome: correlation between hyperandrogenism, insulin resistance and obesity. Clin Chim Acta. 2020;502:214\u201321.","journal-title":"Clin Chim Acta"},{"issue":"3","key":"1975_CR15","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1177\/1933719117715129","volume":"25","author":"Z Mao","year":"2018","unstructured":"Mao Z, Fan L, Yu Q, Luo S, Wu X, Tang J, et al. Abnormality of Klotho signaling is involved in polycystic ovary syndrome. Reproductive Sci. 2018;25(3):372\u201383.","journal-title":"Reproductive Sci"},{"issue":"4","key":"1975_CR16","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1080\/09513590.2019.1653844","volume":"36","author":"X Qiu","year":"2019","unstructured":"Qiu X, Wei Y, Liu C, Ding C, Zhao S. Hyperandrogen enhances apoptosis of human ovarian granulosa cells via up-regulation and demethylation of PDCD4. Gynecol Endocrinol. 2019;36(4):333\u20137.","journal-title":"Gynecol Endocrinol"},{"issue":"9","key":"1975_CR17","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1080\/17512433.2021.1933433","volume":"14","author":"M Siamashvili","year":"2021","unstructured":"Siamashvili M, Davis SN. Update on the effects of GLP-1 receptor agonists for the treatment of polycystic ovary syndrome. Expert Rev Clin Pharmacol. 2021;14(9):1081\u20139.","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"Supplement2","key":"1975_CR18","doi-asserted-by":"publisher","first-page":"S210","DOI":"10.1542\/peds.2019-2056J","volume":"145","author":"M Trent","year":"2020","unstructured":"Trent M, Gordon CM. Diagnosis and management of polycystic ovary syndrome in adolescents. Pediatrics. 2020;145(Supplement2):S210\u20138.","journal-title":"Pediatrics"},{"issue":"8","key":"1975_CR19","doi-asserted-by":"publisher","first-page":"4650","DOI":"10.1210\/jc.2005-0628","volume":"90","author":"R Azziz","year":"2005","unstructured":"Azziz R, Marin C, Hoq L, Badamgarav E, Song P. Health Care-Related economic burden of the polycystic ovary syndrome during the reproductive life span. J Clin Endocrinol Metabolism. 2005;90(8):4650\u20138.","journal-title":"J Clin Endocrinol Metabolism"},{"key":"1975_CR20","doi-asserted-by":"crossref","unstructured":"Revised. 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertility and Sterility. 2004;81(1):19\u201325.","DOI":"10.1016\/j.fertnstert.2003.10.004"},{"issue":"1","key":"1975_CR21","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.fertnstert.2013.09.015","volume":"101","author":"ME Bleil","year":"2014","unstructured":"Bleil ME, Gregorich SE, Adler NE, Sternfeld B, Rosen MP, Cedars MI. Race\/ethnic disparities in reproductive age: an examination of ovarian reserve estimates across four race\/ethnic groups of healthy, regularly cycling women. Fertil Steril. 2014;101(1):199\u2013207.","journal-title":"Fertil Steril"},{"key":"1975_CR22","doi-asserted-by":"publisher","first-page":"818912","DOI":"10.1155\/2013\/818912","volume":"2013","author":"R Tal","year":"2013","unstructured":"Tal R, Seifer DB. Potential mechanisms for Racial and ethnic differences in antim\u00fcllerian hormone and ovarian reserve. Int J Endocrinol. 2013;2013:818912.","journal-title":"Int J Endocrinol"},{"issue":"3","key":"1975_CR23","doi-asserted-by":"publisher","first-page":"e57005","DOI":"10.1371\/journal.pone.0057005","volume":"8","author":"A La Marca","year":"2013","unstructured":"La Marca A, Sighinolfi G, Papaleo E, Cagnacci A, Volpe A, Faddy MJ. Prediction of age at menopause from assessment of ovarian reserve May be improved by using body mass index and smoking status. PLoS ONE. 2013;8(3):e57005.","journal-title":"PLoS ONE"},{"key":"1975_CR24","doi-asserted-by":"crossref","unstructured":"Singh MP, Kalra R, Agresta F, Leos A, Alwis SM, Polyakov A et al. Age and serum anti-M\u00fcllerian hormone levels as predictors of time to return of menses after chemotherapy. Reprod Fertility. 2025;6(1):e240046.","DOI":"10.1530\/RAF-24-0046"},{"issue":"6","key":"1975_CR25","doi-asserted-by":"publisher","first-page":"1760","DOI":"10.1016\/j.fertnstert.2007.05.003","volume":"89","author":"CY Andersen","year":"2008","unstructured":"Andersen CY, Lossl K. Increased intrafollicular androgen levels affect human granulosa cell secretion of anti-m\u00fcllerian hormone and inhibin-B. Fertil Steril. 2008;89(6):1760\u20135.","journal-title":"Fertil Steril"},{"issue":"12","key":"1975_CR26","doi-asserted-by":"publisher","first-page":"2622","DOI":"10.1172\/JCI2081","volume":"101","author":"K Vendola","year":"1998","unstructured":"Vendola K, Zhou J, Adesanya O, et al. Androgens stimulate early stages of follicular growth in the primate ovary. J CLIN INVEST. 1998;101(12):2622\u20139.","journal-title":"J CLIN INVEST"},{"issue":"2","key":"1975_CR27","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1093\/humupd\/dmh010","volume":"10","author":"S Jonard","year":"2004","unstructured":"Jonard S. The follicular excess in polycystic ovaries, due to intra-ovarian hyperandrogenism, May be the main culprit for the follicular arrest. Hum Reprod Update. 2004;10(2):107\u201317.","journal-title":"Hum Reprod Update"},{"issue":"1","key":"1975_CR28","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/j.fertnstert.2012.03.059","volume":"98","author":"RL Rosenfield","year":"2012","unstructured":"Rosenfield RL, Wroblewski K, Padmanabhan V, Littlejohn E, Mortensen M, Ehrmann DA. Antim\u00fcllerian hormone levels are independently related to ovarian hyperandrogenism and polycystic ovaries. Fertil Steril. 2012;98(1):242\u2013e94.","journal-title":"Fertil Steril"},{"issue":"12","key":"1975_CR29","doi-asserted-by":"publisher","first-page":"5957","DOI":"10.1210\/jc.2003-030727","volume":"88","author":"P Pigny","year":"2003","unstructured":"Pigny P, Merlen E, Robert Y, Cortet-Rudelli C, Decanter C, Jonard S, et al. Elevated serum level of Anti-Mullerian hormone in patients with polycystic ovary syndrome: relationship to the ovarian follicle excess and to the follicular arrest. J Clin Endocrinol Metabolism. 2003;88(12):5957\u201362.","journal-title":"J Clin Endocrinol Metabolism"},{"issue":"2","key":"1975_CR30","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/S0015-0282(01)02993-4","volume":"77","author":"A de Vet","year":"2002","unstructured":"Vet A de, Laven J, de Jong F, et al. Antim\u00fcllerian hormone serum levels: a putative marker for ovarian aging. Fertil Steril. 2002;77(2):357\u201362.","journal-title":"FERTIL STERIL"},{"issue":"3","key":"1975_CR31","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1210\/endo.143.3.8691","volume":"143","author":"A Durlinger","year":"2002","unstructured":"Durlinger A, Gruijters M, Kramer P, et al. Anti-M\u00fcllerian hormone inhibits initiation of primordial follicle growth in the mouse ovary. Endocrinology. 2002;143(3):1076\u201384.","journal-title":"Endocrinology"},{"key":"1975_CR32","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1016\/S0015-0282(99)00639-1","volume":"73","author":"L Christine","year":"2000","unstructured":"Christine L, Cook MD, Yong Siow PD, Susan Taylor BA, Mary E, Fallat MD. Serum mu\u00a8llerian-inhibiting substance levels during normal menstrual cycles. Fertil Steril. 2000;73:859\u201361.","journal-title":"Fertil Steril"},{"issue":"3","key":"1975_CR33","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1093\/humrep\/del421","volume":"22","author":"A La Marca","year":"2007","unstructured":"La Marca A, Giulini S, Tirelli A, Bertucci E, Marsella T, Xella S, et al. Anti-M\u00fcllerian hormone measurement on any day of the menstrual cycle strongly predicts ovarian response in assisted reproductive technology. Hum Reprod. 2007;22(3):766\u201371.","journal-title":"Hum Reprod"},{"issue":"12","key":"1975_CR34","doi-asserted-by":"publisher","first-page":"3103","DOI":"10.1093\/humrep\/del291","volume":"21","author":"A La Marca","year":"2006","unstructured":"La Marca A, Stabile G, Artenisio AC, Volpe A. Serum anti-Mullerian hormone throughout the human menstrual cycle. Hum Reprod. 2006;21(12):3103\u20137.","journal-title":"Hum Reprod"},{"issue":"1","key":"1975_CR35","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1093\/humrep\/dep366","volume":"25","author":"J van Disseldorp","year":"2009","unstructured":"van Disseldorp J, Lambalk CB, Kwee J, Looman CWN, Eijkemans MJC, Fauser BC, et al. Comparison of inter- and intra-cycle variability of anti-Mullerian hormone and antral follicle counts. Hum Reprod. 2009;25(1):221\u20137.","journal-title":"Hum Reprod"},{"issue":"8","key":"1975_CR36","doi-asserted-by":"publisher","first-page":"1716","DOI":"10.1093\/humrep\/dex239","volume":"32","author":"A Fraissinet","year":"2017","unstructured":"Fraissinet A, Robin G, Pigny P, Lefebvre T, Catteau-Jonard S, Dewailly D. Use of the serum anti-M\u00fcllerian hormone assay as a surrogate for polycystic ovarian morphology: impact on diagnosis and phenotypic classification of polycystic ovary syndrome. Hum Reprod. 2017;32(8):1716\u201322.","journal-title":"Hum Reprod"},{"key":"1975_CR37","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.cca.2017.06.009","volume":"471","author":"SE Karakas","year":"2017","unstructured":"Karakas SE. New biomarkers for diagnosis and management of polycystic ovary syndrome. Clin Chim Acta. 2017;471:248\u201353.","journal-title":"Clin Chim Acta"},{"issue":"2","key":"1975_CR38","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1093\/humrep\/deg042","volume":"18","author":"R Fanchin","year":"2003","unstructured":"Fanchin R. Serum anti-Mullerian hormone is more strongly related to ovarian follicular status than serum inhibin B, estradiol, FSH and LH on day 3. Hum Reprod. 2003;18(2):323\u20137.","journal-title":"Hum Reprod"},{"issue":"3","key":"1975_CR39","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1016\/S0015-0282(01)03201-0","volume":"77","author":"D Seifer","year":"2002","unstructured":"Seifer D, MacLaughlin D, Christian B, et al. Early follicular serum m\u00fcllerian-inhibiting substance levels are associated with ovarian response during assisted reproductive technology cycles. FERTIL STERIL. 2002;77(3):468\u201371.","journal-title":"FERTIL STERIL"},{"key":"1975_CR40","doi-asserted-by":"crossref","unstructured":"Sonigo C, Beau I, Binart N, Grynberg M. Anti-M\u00fcllerian hormone in fertility preservation: clinical and therapeutic applications. Clin Med Insights: Reproductive Health. 2019;13:1179558119854755.","DOI":"10.1177\/1179558119854755"},{"issue":"5","key":"1975_CR41","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1111\/IGC.0b013e3181a702d1","volume":"19","author":"I Geerts","year":"2009","unstructured":"Geerts I, Vergote I, Neven P, Billen J. The role of inhibins B and antimullerian hormone for diagnosis and Follow-up of granulosa cell tumors. Int J Gynecol Cancer. 2009;19(5):847\u201355.","journal-title":"Int J Gynecol Cancer"},{"key":"1975_CR42","doi-asserted-by":"crossref","unstructured":"Rey R, Lhomm\u00e9 C, Marcillac I et al. Antim\u00fcllerian hormone as a serum marker of granulosa cell tumorsof the ovary: comparative study with serum alpha-inhibin and estradiol. AM J OBSTET GYNECOL. 1996;174 (3):958\u2013\u200965.","DOI":"10.1016\/S0002-9378(96)70333-2"},{"key":"1975_CR43","doi-asserted-by":"crossref","unstructured":"Gustafson M, Lee M, Scully R, et al, et al. M\u00fcllerian inhibiting substance as a marker for ovarian sex-cord tumor. NEW ENGL J MED. 1992;326(7):466\u201371.","DOI":"10.1056\/NEJM199202133260707"},{"key":"1975_CR44","doi-asserted-by":"crossref","unstructured":"Lane A, Lee M, Fuller A et al. Diagnostic utility of M\u00fcllerian inhibiting substance determination in patients with primary and recurrent granulosa cell tumors. GYNECOL ONCOL. 1999;73 (1):51\u2013\u20095.","DOI":"10.1006\/gyno.1998.5290"},{"issue":"10","key":"1975_CR45","doi-asserted-by":"publisher","first-page":"2447","DOI":"10.1210\/clinem\/dgad463","volume":"108","author":"HJ Teede","year":"2023","unstructured":"Teede HJ, Tay CT, Laven JJE, Dokras A, Moran LJ, Piltonen TT, et al. Recommendations from the 2023 international Evidence-based guideline for the assessment and management of polycystic ovary syndrome. J Clin Endocrinol Metabolism. 2023;108(10):2447\u201369.","journal-title":"J Clin Endocrinol Metabolism"},{"issue":"7","key":"1975_CR46","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1093\/humrep\/dead081","volume":"38","author":"CR Tzeng","year":"2023","unstructured":"Tzeng CR, Huang Z, Asada Y, Zhang C, Ho MT, Li RHW, et al. Factors affecting the distribution of serum anti-m\u00fcllerian hormone levels among infertile Asian women: a multi-nation, multi-centre, and multi-ethnicity prospective cohort study. Hum Reprod (Oxford England). 2023;38(7):1368\u201378.","journal-title":"Hum Reprod (Oxford England)"},{"issue":"10","key":"1975_CR47","doi-asserted-by":"publisher","first-page":"2861","DOI":"10.1093\/humrep\/der223","volume":"26","author":"C Villarroel","year":"2011","unstructured":"Villarroel C, Merino PM, Lopez P, Eyzaguirre FC, Van Velzen A, Iniguez G, et al. Polycystic ovarian morphology in adolescents with regular menstrual cycles is associated with elevated anti-Mullerian hormone. Hum Reprod. 2011;26(10):2861\u20138.","journal-title":"Hum Reprod"},{"issue":"4","key":"1975_CR48","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1093\/humrep\/det015","volume":"28","author":"R Homburg","year":"2013","unstructured":"Homburg R, Ray A, Bhide P, Gudi A, Shah A, Timms P, et al. The relationship of serum anti-Mullerian hormone with polycystic ovarian morphology and polycystic ovary syndrome: a prospective cohort study. Hum Reprod. 2013;28(4):1077\u201383.","journal-title":"Hum Reprod"},{"issue":"12","key":"1975_CR49","doi-asserted-by":"publisher","first-page":"5789","DOI":"10.1210\/endo.140.12.7204","volume":"140","author":"A Durlinger","year":"1999","unstructured":"Durlinger A, Kramer P, Karels B, al e. Control of primordial follicle recruitment by Anti-Mu\u00a8 Llerian hormone in the mouse ovary. Endocrinology. 1999;140(12):5789\u201396.","journal-title":"Endocrinology"},{"issue":"5","key":"1975_CR50","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1530\/REP-09-0415","volume":"139","author":"L Pellatt","year":"2010","unstructured":"Pellatt L, Rice S, Mason HD. Anti-M\u00fcllerian hormone and polycystic ovary syndrome: a mountain too high? Reproduction. 2010;139(5):825\u201333.","journal-title":"Reproduction"},{"issue":"5","key":"1975_CR51","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1016\/j.fertnstert.2011.08.015","volume":"96","author":"L Pellatt","year":"2011","unstructured":"Pellatt L, Rice S, Dilaver N, Heshri A, Galea R, Brincat M, et al. Anti-M\u00fcllerian hormone reduces follicle sensitivity to follicle-stimulating hormone in human granulosa cells. Fertil Steril. 2011;96(5):1246\u2013e511.","journal-title":"Fertil Steril"}],"container-title":["BMC Endocrine Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12902-025-01975-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12902-025-01975-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12902-025-01975-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T09:40:14Z","timestamp":1751362814000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcendocrdisord.biomedcentral.com\/articles\/10.1186\/s12902-025-01975-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,1]]},"references-count":51,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1975"],"URL":"https:\/\/doi.org\/10.1186\/s12902-025-01975-4","relation":{},"ISSN":["1472-6823"],"issn-type":[{"value":"1472-6823","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,1]]},"assertion":[{"value":"19 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study strictly adhered to the relevant provisions of the Helsinki Declaration (). Prior to conducting the research, we had obtained ethical approval from the Ethics Committee of Hangzhou Women\u2019s Hospital(Hangzhou Maternity and Child Health Care Hospital). All human participants in this study have fully understood the research objectives, methods, potential risks, and potential benefits, and have voluntarily signed informed consent forms without any coercion. During the research process, we ensured that the rights, dignity, safety, and privacy of the subjects were fully protected, and all research operations complied with ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"153"}}